Literature DB >> 2499187

A double-blind placebo-controlled comparison of the efficacy and safety of 50, 100, and 200 micrograms of misoprostol QID in the prevention of ibuprofen-induced gastric and duodenal mucosal lesions and symptoms.

F L Lanza1, D Fakouhi, A Rubin, R E Davis, M F Rack, C Nissen, S Geis.   

Abstract

Ibuprofen, a commonly proscribed nonsteroidal anti-inflammatory drug that is also available in many countries, including the United States, without a prescription, is known to cause hemorrhage and erosion of the gastroduodenal mucosa. This study was conducted to compare the efficacy of 200, 100, and 50 micrograms of misoprostol and placebo administered qid for 6 days, with a final dose on the morning of the 7th day, in the prevention of gastric and duodenal lesions induced by the concurrent administration of 800 mg of ibuprofen qid. A total of 120 healthy subjects with endoscopically normal gastric and duodenal mucosae were enrolled in the study. The endoscopic examination was repeated 2 h after the final dose on day 7, and the mucosae were graded on a 0 to 4+ scale. In the stomach, all three misoprostol groups were significantly more protective than placebo and did not differ significantly from each other. In the duodenum, the endoscopic scores of the 200- and 100-micrograms misoprostol groups, but not the 50-micrograms group differed significantly from placebo. The 200- and 100-microgram groups did not differ significantly from each other, but both differed from the 50-micrograms group for duodenal mucosal injury. Subjective symptoms thought to be primarily attributable to the NSAID (e.g., pain, indigestion/heartburn and nausea) were recorded by each subject in a diary. Subjects in the 200-micrograms misoprostol group attained the greatest degree of mucosal protection and had a significantly higher incidence of indigestion/heartburn and abdominal pain than the placebo group. One can conclude that misoprostol in both antisecretory (200- and 100-micrograms) and non-antisecretory (50-micrograms) doses protects the gastric mucosa from injury from high anti-inflammatory doses of ibuprofen (3200 mg/day). Only the antisecretory doses (100 and 200 micrograms qid) were effective in the duodenum, suggesting that acid suppression is necessary for mucosal protection to occur in the duodenum.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2499187

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  16 in total

1.  Association between adherence to evidence-based guidelines for the prescription of non-steroidal anti-inflammatory drugs and the incidence of gastric mucosal lesions in Japanese patients.

Authors:  Hidetaka Tsumura; Tsuyoshi Fujita; Isamu Tamura; Yoshinori Morita; Masaru Yoshida; Takashi Toyonaga; Hidekazu Mukai; Hideto Inokuchi; Hiromu Kutsumi; Takeshi Azuma
Journal:  J Gastroenterol       Date:  2010-05-25       Impact factor: 7.527

2.  Clinical pharmacology and therapeutics.

Authors:  G C Fenn
Journal:  Postgrad Med J       Date:  1990-08       Impact factor: 2.401

Review 3.  Gastric cytoprotection. What does it really mean for the prescriber?

Authors:  M Guslandi
Journal:  Drugs       Date:  1991-04       Impact factor: 9.546

4.  NSAIDs and peptic ulcers.

Authors: 
Journal:  BMJ       Date:  1990-03-24

5.  Non-steroidal Anti-inflammatory Drugs: Monitoring to help prevent serious adverse effects.

Authors:  B Cardario; A A McKinnon
Journal:  Can Fam Physician       Date:  1991-01       Impact factor: 3.275

6.  Long term acid suppressing treatment in general practice.

Authors:  S D Ryder; S O'Reilly; R J Miller; J Ross; M R Jacyna; A J Levi
Journal:  BMJ       Date:  1994-03-26

7.  Gastrointestinal safety of AZD3582, a cyclooxygenase inhibiting nitric oxide donator: proof of concept study in humans.

Authors:  C J Hawkey; J I Jones; C T Atherton; M M Skelly; J R Bebb; U Fagerholm; B Jonzon; P Karlsson; I T Bjarnason
Journal:  Gut       Date:  2003-11       Impact factor: 23.059

8.  Efficacy and safety of rabeprazole in non-steroidal anti-inflammatory drug-induced ulcer in Japan.

Authors:  Yuji Mizokami
Journal:  World J Gastroenterol       Date:  2009-10-28       Impact factor: 5.742

9.  Antacid (A02A) and antiulcer (A02B) drug prescription patterns: predicting factors, dosage and treatment duration.

Authors:  M M Morales Suárez-Varela; M A Pérez-Benajas; V J Girbes Pelechano; A Llopis-González
Journal:  Eur J Epidemiol       Date:  1998-06       Impact factor: 8.082

Review 10.  Rheumatoid arthritis in the aged. Incidence and optimal management.

Authors:  G Nesher; T L Moore
Journal:  Drugs Aging       Date:  1993 Nov-Dec       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.